Key facts
- iECURE’s last known valuation is $155.0M (Jul 2025).
- It has raised $115.0M; the latest was Later Stage VC ($65.0M) in Jul 2025.
- Notable investors include OrbiMed, Novo Holdings, LYFE Capital, Versant Ventures, Double Point Ventures — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for iECURE
- ·The full record, as it builds
Funding rounds
No funding rounds for iECURE are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iECURE
Developer of an in vivo gene editing platform designed to create long-lasting treatments for patients with rare genetic liver disorders. The company's platform offers mutation-agnostic gene insertion methods and a research partnership with the University of Pennsylvania's Gene Therapy Program, enabling individuals with monogenic liver diseases to achieve durable restoration of healthy gene function.
- Sector
- Healthcare
- HQ
- Blue Bell, PA, United States
- Founded
- 2020
- Employees
- 38
- Website
- iecure.com/
- Ownership
- Privately Held (backing)
iECURE doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iECURE shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iECURE in its N-PORT filings yet. We sweep new filings monthly.